Top

International Urology and Nephrology

Published in:

01-07-2019 | Cystectomy | Urology - Original Paper

Which treatment is best for patients with AJCC stage IV bladder cancer?

Authors: WeiPu Mao, BingWei Ma, Xin Huang, SiMin Gu, Ming Luo, Jie Fan, Jiang Geng

Published in: International Urology and Nephrology | Issue 7/2019

Abstract

Purpose

We sought to identify the method that could obtain the best survival rate for AJCC stage IV bladder cancer (BCa) patients.

Methods

Patients with AJCC stage IV BCa diagnosed between 2004 and 2015 were identified using the Surveillance, epidemiology and end results (SEER) database. Kaplan–Meier curves and log-rank test were used for overall survival (OS) and cancer-specific survival (CSS). Multivariable Cox regression was used to determine factors associated with all-cause mortality (ACM) and cancer-specific mortality (CSM).

Results

We found that among the 11824 patients, the number of patients who received chemotherapy (CT), radiotherapy (RT) and radical cystectomy (RC) was 6243 (52.8%), 2005 (17.0%) and 4987 (42.2%), respectively. Patients who received CT or RC had improved OS (26.4% vs. 11.7%, p < 0.001 and 27.3% vs. 13.7%, p < 0.001, respectively), but patients who underwent RT alone had lower OS (14.4% vs. 20.5%, p < 0.001). Furthermore, CT combined with RC was associated with the lowest ACM (hazard ratio (HR) = 0.26, 95% CI 0.24–0.28, p < 0.001) and the lowest CSM (HR = 0.24, 95% CI 0.22–0.26, p < 0.001). Patients who only received RT had the highest ACM (HR = 0.84, 95% CI 0.77–0.92, p < 0.001) and the highest CSM (HR = 0.85, 95% CI 0.77–0.94, p = 0.002).

Conclusions

We concluded that CT combined with RC was the best method with the highest survival rate for patients with AJCC stage IV BCa and that CT combined with RC had more benefits in improving OS and CSS than did RT alone.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108. https://doi.org/10.1016/j.eururo.2016.06.010 CrossRefPubMed

Cao J, Wang Q, Wu G, Li S, Wang Q (2018) miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a. Int Urol Nephrol 50(10):1811–1819. https://doi.org/10.1007/s11255-018-1959-x CrossRefPubMed

Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C (2017) Global burden of urologic cancers, 1990–2013. Eur Urol 71(3):437–446. https://doi.org/10.1016/j.eururo.2016.10.008 CrossRefPubMed

Ranzi AD, da Silva JN, Graziottin TM, Annels N, Bica CG (2017) Immunohistochemistry biomarkers in nonmuscle invasive bladder cancer. Appl Immunohistochem Mol Morphol 25 (3):178–183. https://doi.org/10.1097/PAI.0000000000000280 CrossRefPubMed

Rosenberg JE, Carroll PR, Small EJ (2005) Update on chemotherapy for advanced bladder cancer. J Urol 174(1):14–20. https://doi.org/10.1097/01.ju.0000162039.38023.5f CrossRefPubMed

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M (2013) Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 37(3):219–225. https://doi.org/10.1016/j.canep.2013.02.002 CrossRefPubMed

Gupta NP, Goel R, Hemal AK, Dogra PN, Seth A, Aron M, Kumar R, Ansari MS (2004) Radical cystectomy in septuagenarian patients with bladder cancer. Int Urol Nephrol 36(3):353–358CrossRef

Racioppi M, D’Agostino D, Totaro A, Pinto F, Sacco E, D’Addessi A, Marangi F, Palermo G, Bassi PF (2012) Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int 88(3):249–258. https://doi.org/10.1159/000335556 CrossRefPubMed

10.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA (2017) Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(10):1240–1267. https://doi.org/10.6004/jnccn.2017.0156 CrossRef

11.

Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS (2013) Recent advances in the diagnosis and treatment of bladder cancer. BMC Med 11:13. https://doi.org/10.1186/1741-7015-11-13 CrossRefPubMedPubMedCentral

12.

Sheng W, Zhang H, Lu Y (2018) Survival outcomes of locally advanced prostate cancer in patients aged < 50 years after local therapy in the contemporary US population. Int Urol Nephrol 50(8):1435–1444. https://doi.org/10.1007/s11255-018-1931-9 CrossRefPubMed

13.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

14.

David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM (2009) Surveillance of urothelial carcinoma: stage and grade migration, 1993–2005 and survival trends, 1993–2000. Cancer 115(7):1435–1447. https://doi.org/10.1002/cncr.24147 CrossRefPubMed

15.

Herr HW, Donat SM, Bajorin DF (2001) Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165(3):811–814CrossRef

16.

Richards KA, Kader AK, Otto R, Pettus JA, Smith JJ 3rd, Hemal AK (2012) Is robot-assisted radical cystectomy justified in the elderly? A comparison of robotic versus open radical cystectomy for bladder cancer in elderly ≥75 years old. J Endourol 26(10):1301–1306. https://doi.org/10.1089/end.2012.0035 CrossRefPubMed

17.

Hemal AK, Kolla SB, Wadhwa P (2008) Evaluation of laparoscopic radical cystectomy for loco-regionally advanced bladder cancer. World J Urol 26(2):161–166. https://doi.org/10.1007/s00345-007-0221-4 CrossRefPubMed

18.

Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V (2001) Cystectomy for bladder cancer: a contemporary series. J Urol 165(4):1111–1116CrossRef

19.

Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, Coleman JA, Mathew S, Vickers A, Schnorr GC, Feuerstein MA, Rapkin B, Parra RO, Herr HW, Laudone VP (2015) Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol 67(6):1042–1050. https://doi.org/10.1016/j.eururo.2014.11.043 CrossRefPubMed

20.

Hu JC, Chughtai B, O’Malley P, Halpern JA, Mao J, Scherr DS, Hershman DL, Wright JD, Sedrakyan A (2016) Perioperative outcomes, health care costs, and survival after robotic-assisted versus open radical cystectomy: a national comparative effectiveness study. Eur Urol 70(1):195–202. https://doi.org/10.1016/j.eururo.2016.03.028 CrossRefPubMed

21.

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG (2003) Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 98(5):955–961. https://doi.org/10.1002/cncr.11569 CrossRefPubMed

22.

Shah BK, Mandal R (2015) Survival trends in metastatic bladder cancer in the United States: a population based study. J Cancer Res Ther 11(1):124–128. https://doi.org/10.4103/0973-1482.140982 CrossRefPubMed

23.

Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050–1055. https://doi.org/10.1200/JCO.1990.8.6.1050 CrossRefPubMed

24.

Loehrer Sr. PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10(7):1066–1073. https://doi.org/10.1200/JCO.1992.10.7.1066 CrossRef

25.

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077. https://doi.org/10.1200/JCO.2000.18.17.3068 CrossRefPubMed

26.

Resorlu B, Turkolmez K, Ergun G, Baltaci S, Gogus C, Beduk Y (2010) The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph node-positive bladder cancer. Int Urol Nephrol 42(4):959–964. https://doi.org/10.1007/s11255-010-9736-5 CrossRefPubMed

27.

Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF (2008) A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 113(9):2471–2477. https://doi.org/10.1002/cncr.23848 CrossRefPubMedPubMedCentral

28.

Coppin CM (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366(16):1477CrossRef

29.

Diaz DA, Pollack A, Reis IM, Mahmoud O, Gonzalgo ML, Ishkanian A, Fernandez G, Manoharan M, Abramowitz MC (2015) Neoadjuvant radiotherapy improves survival in patients with T2b/T3 bladder cancer: a population-based analysis. Clin Genitourin Cancer 13(4):378–384 e371. https://doi.org/10.1016/j.clgc.2015.02.014 CrossRefPubMed

30.

Skinner DG, Lieskovsky G (1984) Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 131(6):1069–1072CrossRef

31.

Bayoumi Y, Heikal T, Darweish H (2014) Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients. Cancer Manage Res 6:459–465. https://doi.org/10.2147/CMAR.S69055 CrossRef

32.

El-Monim HA, El-Baradie MM, Younis A, Ragab Y, Labib A, El-Attar I (2013) A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. Urol Oncol 31(3):359–365. https://doi.org/10.1016/j.urolonc.2011.01.008 CrossRefPubMed

Title: Which treatment is best for patients with AJCC stage IV bladder cancer?
Authors: WeiPu Mao
BingWei Ma
Xin Huang
SiMin Gu
Ming Luo
Jie Fan
Jiang Geng
Publication date: 01-07-2019
Publisher: Springer Netherlands
Keywords: Cystectomy
Radiotherapy
Cytostatic Therapy
Published in: International Urology and Nephrology / Issue 7/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02105-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Which treatment is best for patients with AJCC stage IV bladder cancer?

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2019

Association of serum IL-18 with protein-energy wasting in end-stage renal disease patients on haemodialysis

Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients

Acute kidney injury in patients with HELLP syndrome

Choosing an equation for glomerular filtration rate in decompensated cirrhosis: “Royal Free Hospital” formula is able to predict short-term mortality

Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies

Intervention of mitochondrial activity attenuates cisplatin-induced acute kidney injury

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page